EU agency confirms suspension of Merck cholesterol drug
LONDON (Reuters) - Europe's drug regulator has confirmed it is suspending marketing authorizations for Merck & Co's cholesterol drug Tredaptive in Europe after its failure in a major study raised safety concerns.
Merck began recalling the drug, which is also sold under the brand names Pelzont and Trevaclyn, on January 11 and recommended that doctors stop prescribing it.
The medicine had been on the market in 40 countries worldwide, but is not approved in the United States.
The European Medicines Agency said patients currently taking the drug should see their doctor to discuss their treatment.
(Reporting by Kate Kelland; Editing by Hans-Juergen Peters)
- Hong Kong protesters stockpile supplies, fear fresh police advance |
- Kurds seize Iraq/Syria border post; Sunni tribe joins fight against Islamic State |
- Special Report: Islamic State uses grain to tighten grip in Iraq
- Protesters stay out on Hong Kong streets, defying Beijing |
- EBay follows Icahn's advice, plans PayPal spinoff in 2015 |